E2F transcription factor 2–Myeloid differentiation primary response 88 promoter interaction (E2F2–MyD88 interaction)

The E2F transcription factor 2–MyD88 promoter interaction is a specific regulatory mechanism where the E2F2 protein binds to the promoter region of the MyD88 gene to drive its expression (Wu et al., 2015, Molecular Immunology). E2F transcription factor 2 (E2F2) is traditionally recognized for its role in the G1/S phase transition of the cell cycle, but it also acts as a critical transcriptional activator in the immune system (UniProt P35510). Myeloid differentiation primary response 88 (MyD88) is a vital adapter protein for Toll-like receptors (TLRs) and interleukin-1 receptors, facilitating the activation of NF-kappaB and the production of pro-inflammatory cytokines (UniProt Q99836). In patients with systemic lupus erythematosus (SLE), E2F2 is often overexpressed in CD4+ T cells, leading to an abnormal increase in MyD88 levels and subsequent hyper-responsiveness to TLR ligands (Wu et al., 2015). This interaction is considered a potential therapeutic target for autoimmune diseases, as disrupting the E2F2-mediated transcription of MyD88 could reduce chronic inflammation. While specific small molecules targeting this exact protein-DNA interface are not yet in clinical use, pan-E2F inhibitors like HLM006474 and MyD88 inhibitors like ST2825 are used in research to modulate this pathway (Ma et al., 2008, Cancer Research; PubMed 16861281). Therapeutic challenges include the risk of systemic toxicity due to E2F2's essential role in normal cell proliferation and the potential for increased susceptibility to infections following MyD88 inhibition.

Other names

E2F2-MyD88 regulatory axisE2F2 binding to MyD88 promoterE2F2-mediated MyD88 transcriptionE2F2-MyD88 interaction

Inhibition of E2F2-mediated transcriptional activation of MyD88 by disrupting the binding of E2F2 to the MyD88 promoter region.